DailyMed
Cure8 research brief
DailyMed label update for RINVOQ
Medications
Upadacitinib
JAK inhibitor
Regulatory Update
Adult patients
Clinicians
Patients On Biologics
Crohn's disease
Why This Matters
A new DailyMed label update for RINVOQ (upadacitinib) outlines FDA-approved uses that include Crohn’s disease and ulcerative colitis and highlights important safety warnings relevant to people with IBD. Patients and clinicians should be aware of the risks and combination-use limitations described on the label.
Who Should Pay Attention
Adult patients with Crohn’s disease or ulcerative colitis, patients considering or taking JAK inhibitors, clinicians prescribing IBD therapies, and caregivers monitoring treatment risks.
Study Snapshot
Story typeClinical Reference
Evidence typeRegulatory update
Source depthMetadata only
What To Know
This is an official drug-label update for RINVOQ (upadacitinib). The label includes a boxed warning about increased risks seen with JAK inhibitors (serious infections, certain cancers, major cardiovascular events, and thrombosis) and notes testing and monitoring recommendations such as screening for latent tuberculosis.
The label also lists FDA-approved indications including moderately to severely active Crohn’s disease and ulcerative colitis for adults, with limitations on combining RINVOQ with other JAK inhibitors, biologic therapies, or potent immunosuppressants.
If you are a patient prescribed or considering RINVOQ, the label is the authoritative source for approved uses, dosing, contraindications, and safety monitoring. Discuss any questions about risks, baseline testing (for TB and other labs), and how this drug fits with your treatment history with your clinician.
For clinicians: the label contains updated indications, boxed warnings, and specific limitations of use that should guide prescribing and monitoring decisions.
Keep In Mind
This source is the official FDA-facing DailyMed drug label (manufacturer-submitted prescribing information). It reports regulatory labeling and safety information rather than new clinical trial findings. For individualized treatment decisions, consult your prescribing clinician.
The label reflects approved indications and boxed warnings; it does not replace personalized medical advice.
Source Details
Review the original publication for the complete reporting, methods, and context.
Regulatory update
Evidence type derived from source or registry metadata.
PublicationDailyMed
Study typeDrug Label Update
Indexed viaDailyMed
Source typeDrug label record
PublishedJul 15, 2026, 12:00 AM
Content availableMetadata only
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
AbbVie Data Underscores Immunology Growth Potential With SKYRIZI And RINVOQ
New long-term and real-world data on SKYRIZI and RINVOQ were presented at DDW, which may influence how clinicians, payers, and patients view these options for Crohn's disease and ulcerative colitis.
No new safety risks for upadacitinib in IBD at 3 years; uptick in herpes zoster in Crohn’s
This analysis summarizes longer-term safety data for upadacitinib (Rinvoq) in people with moderate to severe ulcerative colitis and Crohn’s disease.
Acne Rates Higher Than Expected in IBD Treatment
This study suggests acne is a common real-world side effect of upadacitinib for IBD and can affect treatment decisions and quality of life, especially for younger patients.